

10/644,687

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Jul 12 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to BABS
NEWS 4 Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction
with the 228th ACS National Meeting
NEWS 5 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
fields
NEWS 6 AUG 02 CAlus and CA patent records enhanced with European and Japan
Patent Office Classifications
NEWS 7 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7.01 for Windows) now available
NEWS 8 AUG 04 Pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover! will change September 1, 2004
NEWS 9 AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 10 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal
status data from INPADOC
NEWS 11 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 12 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 13 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 14 SEP 14 STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS 15 SEP 27 STANDARDS will no longer be available on STN
NEWS 16 SEP 27 SWETSCAN will no longer be available on STN

NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

10/644,687

FILE 'HOME' ENTERED AT 17:23:22 ON 28 SEP 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:23:38 ON 28 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 SEP 2004 HIGHEST RN 752974-11-1

DICTIONARY FILE UPDATES: 27 SEP 2004 HIGHEST RN 752974-11-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\STNEXP4\QUERIES\106646872.str



chain nodes :

15 16 17 18 19 20 21 22 23 24 25 26 27 28

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

4-27 10-15 10-16 11-26 13-17 17-18 17-24 17-25 18-19 19-20 20-21 21-22
22-23 27-28

ring bonds :

1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 7-11 8-9 8-14 9-10 11-12 12-13
13-14

10/644,687

exact/norm bonds :

1-10 6-7 11-26

exact bonds :

1-2 1-6 2-3 3-4 4-5 4-27 5-6 8-9 9-10 10-15 10-16 13-17 17-18 17-24
17-25 18-19 19-20 20-21 21-22 22-23 27-28

normalized bonds :

7-8 7-11 8-14 11-12 12-13 13-14

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 17:24:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 11 TO 389

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1


=> d scan

L2 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN 6H-Dibenzo[b,d]pyran-9-methanol, 3-[1,1-di(methyl-d2)heptyl-2-d]-
6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel- (9CI)

MF C25 H33 D5 O3

Relative stereochemistry.



10/644,687

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 ful
FULL SEARCH INITIATED 17:24:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 193 TO ITERATE

100.0% PROCESSED 193 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

L3 8 SEA SSS FUL L1

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	155.84	156.05

FILE 'CAPLUS' ENTERED AT 17:24:34 ON 28 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Sep 2004 VOL 141 ISS 14
FILE LAST UPDATED: 27 Sep 2004 (20040927/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 266 L3

=> s l4 and dexamabinol
61 DEXANABINOL
L5 48 L4 AND DEXANABINOL

=> s l5 and enantiomer
21135 ENANTIOMER
23433 ENANTIOMERS
33946 ENANTIOMER
(ENANTIOMER OR ENANTIOMERS)
L6 5 L5 AND ENANTIOMER

=> s l5 and enantiomer?
50939 ENANTIOMER?
L7 6 L5 AND ENANTIOMER?

=> s l4 and cannabinoid
4991 CANNABINOID

10/644,687

4030 CANNABINOID
5833 CANNABINOID
(CANNABINOID OR CANNABINOIDS)

L8 231 L4 AND CANNABINOID

=> d 17 ibib hitstr abs 1-6

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:473361 CAPLUS

DOCUMENT NUMBER: 141:28689

TITLE: High **enantiomeric** purity **dexanabinol**
for pharmaceutical compositions

INVENTOR(S): Aviv, Haim; Bar, Raphael; Schickler, Michael; Amselem,
Shimon

PATENT ASSIGNEE(S): Israel

SOURCE: U.S. Pat. Appl. Publ., 28 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004110827	A1	20040610	US 2003-644687	20030819
WO 2004050011	A2	20040617	WO 2003-IL1023	20031203
WO 2004050011	A3	20040729		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: IL 2002-153277 A 20021204
US 2003-644687 A 20030819


IT 112924-45-5P, **Dexanabinol**

RL: PUR (Purification or recovery); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(high **enantiomeric** purity **dexanabinol** for
pharmaceutical compns.)

RN 112924-45-5 CAPLUS

CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-
tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 112830-95-2

RL: REM (Removal or disposal); PROC (Process)
(high **enantiomeric** purity **dexanabinol** for
pharmaceutical compns.)

RN 112830-95-2 CAPLUS

CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-
tetrahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



AB The present invention relates to a synthetic cannabinoid, **dexanabinol**, of **enantiomeric** purity in excess of 99.90%, or to a pharmaceutically acceptable salt, ester or solvate of said compound. The present invention also relates to pharmaceutical grade compns. comprising said compound of high **enantiomeric** purity, and uses thereof for prevention and treatment of neurol. disorders, chronic degenerative diseases, CNS poisoning, cognitive impairment, inflammatory diseases or disorders, autoimmune diseases or disorders, pain, emesis, glaucoma and wasting syndromes.

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:392439 CAPLUS

DOCUMENT NUMBER: 140:400095

TITLE: Stereoisomers of p-hydroxy-milnacipran, and
therapeutic use

INVENTOR(S): Rariy, Roman V.; Heffernan, Michael; Buchwald, Stephen
L.; Swager, Timothy M.

PATENT ASSIGNEE(S): Collegium Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

10/644,687

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039320	A2	20040513	WO 2003-US33681	20031022
WO 2004039320	A3	20040624		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004142904	A1	20040722	US 2003-691465	20031022
PRIORITY APPLN. INFO.:			US 2002-421640P	P 20021025
			US 2002-423062P	P 20021101
			US 2003-445142P	P 20030205

OTHER SOURCE(S): MARPAT 140:400095

IT 112924-45-5, Dexanabinol


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(p-hydroxymilnacipran stereoisomers, therapeutic use, and use with other agents)

RN 112924-45-5 CAPLUS

CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The invention relates generally to the **enantiomers** of p-hydroxymilnacipran or congeners thereof. Biol. assays revealed that racemic p-hydroxymilnacipran is approx. equipotent in inhibiting serotonin and norepinephrine uptake (IC₅₀ = 28.6 nM for norepinephrine, IC₅₀ = 21.7 nM for serotonin). Interestingly, (+)-p-hydroxymilnacipran is a more potent inhibitor of norepinephrine uptake than serotonin uptake (IC₅₀ = 10.3 nM for norepinephrine, IC₅₀ = 22 nM for serotonin). In contrast, (-)-p-hydroxymilnacipran is a more potent inhibitor of serotonin uptake compared to norepinephrine uptake (IC₅₀ = 88.5 nM for norepinephrine, IC₅₀ = 40.3 nM for serotonin). The invention also relates to salts and prodrug forms of the above compds. In certain embodiments, the compds. of the

invention and a pharmaceutically acceptable excipient are combined to prepare a formulation for administration to a patient. Finally, the invention relates to methods of treating mammals suffering from various afflictions, e.g., depression, chronic pain, or fibromyalgia, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of the invention. Compound preparation is included.

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:13489 CAPLUS

DOCUMENT NUMBER: 135:70407

TITLE: **Dexanabinol** Pharmos

AUTHOR(S): Pop, Emil

CORPORATE SOURCE: Alchem Laboratories Corporation, Alachua, FL, 32615, USA

SOURCE: Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2000), 1(4), 494-503

CODEN: COIDAZ

PUBLISHER: PharmaPress Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


IT 112924-45-5P, **Dexanabinol**

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (therapeutic uses of **dexanabinol**)

RN 112924-45-5 CAPLUS

CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic uses of **dexanabinol**)


AB A review, with 106 refs. **Dexanabinol** is a non-psychotropic cannabinoid NMDA receptor antagonist under development by Pharmos Corp for the potential treatment of cerebral ischemia, glaucoma, Alzheimer's disease, cardiac failure, head injury and multiple sclerosis (MS); it is in phase III trials for traumatic brain injury (TBI). **Dexanabinol** was licensed to Pharmos for development from its originator, the Hebrew University of Jerusalem. Pharmos is seeking to enter into a strategic agreement with another company to develop and commercialize **dexanabinol**. Unlike its enantiomer, HU-210 (Yissum Research Development Co), **dexanabinol** does not interact with

cannabinoid receptors. It has also exhibited more effective antioxidant and anti-inflammatory properties than MK-801 (dizocilpine; Merck & Co Inc). In addition, **dexanabinol** is generally well tolerated and appears toxicol. safe. Pharmos has been awarded a Small Business Innovation Research grant from the National Institutes of Health (NIH) National Institute of Neurol. Disorders and Stroke, Division of Stroke and Trauma. The grant covers the development of new prodrugs and novel formulations of **dexanabinol** and will support addnl. study of **dexanabinol** compds. for various indications. The prodrugs being studied are part of the group of compds. that include **dexanabinol**. A Notice of Allowance was received in Mar. 1999 on a patent covering the use of the drug in the treatment of MS. The use of **dexanabinol** and its derivs. to treat MS is described in US-05932610. An oral formulation of **dexanabinol** is claimed in US-05891468. **Dexanabinol** analogs with special utility in acute and chronic pain are claimed in US-04876276, while **dexanabinol** analogs for neuroprotection are claimed in US-06096740. Pharmos ests. that the worldwide market for **dexanabinol** in the treatment of severe head trauma may reach \$1 billion per yr.

REFERENCE COUNT: 106 THERE ARE 106 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:614231 CAPLUS
 DOCUMENT NUMBER: 133:275752
 TITLE: Nonpsychotropic synthetic cannabinoids
 AUTHOR(S): Pop, Emil
 CORPORATE SOURCE: Alchem Laboratories Corporation, Alachua, FL, USA
 SOURCE: Current Pharmaceutical Design (2000), 6(13), 1347-1359
 CODEN: CPDEFP; ISSN: 1381-6128
 PUBLISHER: Bentham Science Publishers
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 IT 112924-45-5, **Dexanabinol**
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nonpsychotropic synthetic cannabinoids)
 RN 112924-45-5 CAPLUS
 CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB - A review with 61 refs. Unlike natural cannabinoids which belong to the

6aR - trans series, the synthetic **dexanabinol** (HU-211), a 6aS-trans **enantiomer**, does not have affinity toward cannabinoid receptors and is devoid of cannabimimetic activity. On the other hand, **dexanabinol** demonstrated significant neuroprotective properties which prompted its development as a therapeutic agent. We now present the extension of a series of 6aS-trans cannabinoids with novel derivs., including water soluble derivs. and congeners of **dexanabinol**.

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:747199 CAPLUS

DOCUMENT NUMBER: 128:74980

TITLE: Dimerization of **dexanabinol** by hydrogen bonding accounts for its hydrophobic character

AUTHOR(S): Pop, Emil; Brewster, Marcus E.

CORPORATE SOURCE: Pharmos Corporation, Alachua, FL, 32615, USA

SOURCE: International Journal of Quantum Chemistry (1997), 65(6), 1057-1064

CODEN: IJQCB2; ISSN: 0020-7608

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 112924-45-5, **Dexanabinol**


RL: PRP (Properties)

(monomer and hydrogen-bonded dimer; dimerization of **dexanabinol** by hydrogen bonding in relation to hydrophobicity)

RN 112924-45-5 CAPLUS

CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB **Dexanabinol** (I), a dihydroxylated synthetic cannabinoid, is a member of the nonpsychotropic (+)-3S,4S **enantiomeric** series. Exptl. evidence suggests that I might form aggregates (e.g., dimers) in which the 2 OH (a phenol and an allylic alc.) groups are involved in H bonding. The extremely low solubility of I in H₂O implies that this interaction may not involve solvent mols. A theor. study of this phenomenon in the framework of the PM3 mol. approximation is described. Simple mol. models (PhOH and 1-cyclohexene-1-methanol) were initially examined, followed by extension of the calcns. to I. I dimers resulting from H bonding are more stable than the isolated mols., with the differences attributed to H-bonding energies. The phenolic hydroxy group of 1 mol. forms an H bond with the allylic OH group of the 2nd mol. and vice versa, resulting in dimers containing 2 H bonds. The H bonds are more stable (6.14

kcal/mol) and the complex formed is more favored energetically when the phenol groups act as H-bond donors and the allylic OH groups as acceptors. These interactions are also energetically more favored than those between I and H₂O (3.70 kcal/mol). The I dimer showed a lower dipole moment than the monomer (1.211 vs. 2.221 D) as well as a much larger log P (11.16 vs. 5.90), indicating strong hydrophobic character. The optimized structure shows that the OH groups involved in H bonds are oriented toward the interior of the dimers, while the lipophilic side chains are oriented toward the exterior. These properties of the dimer may explain the low water solubility of I.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:326857 CAPLUS

DOCUMENT NUMBER: 126:308812

TITLE: Tumor necrosis factor alpha (TNF- α)-inhibiting pharmaceuticals containing Δ 6-tetrahydrocannabinol-type compounds

INVENTOR(S): Shohami, Esther; Gallily, Ruth; Mechoulam, Raphael

PATENT ASSIGNEE(S): Yissum Research Development Co. of the Hebrew University, Israel; Shohami, Esther; Gallily, Ruth; Mechoulam, Raphael

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9711668	A2	19970403	WO 1996-IL108	19960910
WO 9711668	A3	19970515		
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA			
IL 115245	A1	20021201	IL 1995-115245	19950911
CA 2231764	AA	19970403	CA 1996-2231764	19960910
AU 9669420	A1	19970417	AU 1996-69420	19960910
AU 708886	B2	19990812		
EP 876143	A2	19981111	EP 1996-930337	19960910
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2000500737	T2	20000125	JP 1997-513269	19960910
US 5932610	A	19990803	US 1997-952660	19971117
US 6331560	B1	20011218	US 1999-318774	19990526
US 2002049245	A1	20020425	US 2001-971821	20011004
US 6545041	B2	20030408		

PRIORITY APPLN. INFO.:
 IL 1995-115245 A 19950911
 WO 1996-IL108 W 19960910
 US 1997-952660 A1 19971117
 US 1999-318774 A1 19990526

OTHER SOURCE(S): MARPAT 126:308812

IT 112924-45-5, Dexanabinol

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

10/644,687


study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(tumor necrosis factor- α -inhibiting pharmaceuticals containing Δ^6 -tetrahydrocannabinol-type compds.)

RN 112924-45-5 CAPLUS

CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Pharmaceutical compns. are described for preventing TNF toxicity, comprising as active ingredient the stereospecific (+) **enantiomer**, having the (3S,4S) configuration of Δ^6 -tetrahydrocannabinol type compds. The compns. are particularly effective in alleviating and even preventing neurotoxicity due to elevated levels of TNF, including septic shock, cachexia and trauma. They are also effective in the treatment of certain chronic degenerative diseases characterized by TNF production, including autoimmune diseases.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
43.76	199.81

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.20	-4.20

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:35:14 ON 28 SEP 2004